Victoria Wirtz

Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96-Week Efficacy and Safety Results of the CASTLE Study

Jean‐Michel Molina, Jaime Andrade‐Villanueva, Juan Echevarría et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2010 · 255 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

Margaret Johnson, Beatriz Grinsztejn, Claudia Rodríguez et al. · AIDS · 2006 · 201 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients

Daniel R Malan, Edrich Krantz, Neal David et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2008 · 150 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Efficacy and Safety of Atazanavir-Based Highly Active Antiretroviral Therapy in Patients with Virologic Suppression Switched from a Stable, Boosted or Unboosted Protease Inhibitor Treatment Regimen: The SWAN Study (AI424-097) 48-Week Results

José M. Gatell, Dominique Salmon Ceron, Adriano Lazzarin et al. · Clinical Infectious Diseases · 2007 · 143 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study

Max Lataillade, Jennifer Chiarella, Rong Yang et al. · PLoS ONE · 2010 · 130 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17